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DOI 10.1016/j.ccr.2010.11.023SUMMARYBRAF is an attractive target for melanoma drug development. However, resistance to BRAF inhibitors is a
significant clinical challenge. We describe a model of resistance to BRAF inhibitors developed by chronic
treatment of BRAFV600E melanoma cells with the BRAF inhibitor SB-590885; these cells are cross-resistant
to other BRAF-selective inhibitors. Resistance involves flexible switching among the three RAF isoforms,
underscoring the ability of melanoma cells to adapt to pharmacological challenges. IGF-1R/PI3K signaling
was enhanced in resistant melanomas, and combined treatment with IGF-1R/PI3K and MEK inhibitors
induced death of BRAF inhibitor-resistant cells. Increased IGF-1R and pAKT levels in a post-relapse human
tumor sample are consistent with a role for IGF-1R/PI3K-dependent survival in the development of resistance
to BRAF inhibitors.INTRODUCTION
Melanoma, a malignancy originating in pigment-producing
melanocytes, is the most aggressive form of skin cancer.
Although surgical treatment of early melanoma leads to 90%
cure rates, unresectable advanced melanoma is notorious for
its intrinsic resistance to chemotherapy, aggressive clinical
behavior, and tendency to rapidlymetastasize. Five-year survival
rates for patients with distant metastatic disease remain below
20% (Altekruse et al., 2010). Additionally, the incidence of
melanoma continues to rise worldwide (Jemal et al., 2001).Significance
Effective strategies to overcome anti-cancer drug resistance
standing the molecular mechanisms of resistance in models
used in the clinic. BRAFV600E mutant melanomas developed
CRAF, and ARAF isoforms to activate the MAPK pathway. O
BRAF inhibition but also proposes a strategy to overcome i
survival of BRAF inhibitor resistant cells, thus the requirement
hibition of MEK and IGF-1R/PI3K warrants further investiga
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CanThis dismal clinical and epidemiological picture underscores
the need for effective therapeutic strategies to target this
aggressive neoplasia. Over 50%ofmelanomas harbor activating
V600E mutations in BRAF (BRAFV600E) (Davies et al., 2002), an
oncogene known to be critical for the proliferation and survival
of melanoma cells through activation of the RAF/MEK/ERK
mitogen activated protein kinase pathway (MAPK) (Dhomen
and Marais, 2009; Fecher et al., 2008; Garnett and Marais,
2004), making BRAF an attractive target for antimelanoma
therapy. Thus, there is an ongoing effort to develop small mole-
cule inhibitors to target the BRAF/MAPK pathway. Several BRAFare sorely needed and can only be developed by under-
that mimic the chronic administration of anti-cancer drugs
resistance to BRAF inhibitors by switching among BRAF,
ur study not only establishes a mechanism of resistance to
t. We find that enhanced IGF-1R/PI3K signaling promotes
to cotarget both pathways. Our findings suggest that coin-
tion as a strategy to treat melanomas refractory to BRAF
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Acquired Resistance to BRAF Inhibitorsand MEK inhibitors are currently being tested; for example, the
BRAF inhibitors RAF-265 (Novartis), XL281 (Exelixis), PLX4032
(Plexxikon/Roche), and GSK2118436 (GSK) are in advanced
stages of clinical trials (ClinicalTrials.gov). Encouraging results
from a clinical trial with the BRAF inhibitor PLX4032 were
recently reported (Flaherty et al., 2010). Data from this study
indicate that chronic treatment with PLX4032 leads to tumor
shrinkage and progression-free survival of7months in patients
with BRAFV600E mutant melanomas. However, most patients
who initially responded to treatment with PLX4032 relapsed,
suggesting that chronic treatment with BRAF inhibitors is asso-
ciated with development of drug resistance.
Drug resistance is a common problem associated with chronic
treatment with anticancer drugs (Engelman and Janne, 2008;
Engelman et al., 2007; Kobayashi et al., 2005; Pao et al.,
2005). Clinical experience with other neoplasms, as well as early
data with PLX4032, suggest that resistance to BRAF inhibitors
will likely be a significant clinical challenge. Therefore, it is critical
to proactively direct research efforts to: (1) develop goodmodels
of resistance to BRAF inhibitors; (2) investigate the mechanisms
underlying resistance; and (3) design alternative therapeutic
strategies to overcome drug resistance. Models of acquired
resistance should mimic chronic treatment conditions used in
the clinical setting. The evaluation of mechanisms of resistance
should address the well-documented adaptability of melanoma
cells (Hendrix et al., 2003), and consider the possibility that
resistance to a drug can be linked to multiple mechanisms.
Understanding the mechanisms underlying acquired resistance
to anticancer agents will be instrumental in developing alterna-
tive therapeutic strategies.
Here we examine mechanisms underlying acquired resistance
to BRAF inhibitors in melanomas with BRAFV600E mutations and
evaluate therapeutic strategies to overcome it.
RESULTS
Chronic BRAF Inhibition Leads to Acquired Drug
Resistance
To investigate if chronic BRAF inhibition could lead to acquired
drug resistance, a panel of BRAF inhibitor sensitive melanoma
cell lines harboring the V600E mutation in the Braf gene and
expressing PTEN (see Table S1 available online) were chronically
treated with increasing concentrations of the specific BRAF
inhibitor SB-590885 (885; Figure 1A) (King et al., 2006). We
focused on PTEN-expressing cells because we have found
that cells that lack PTEN are often substantially less sensitive
to BRAF inhibitors than PTEN expressing cells (our unpublished
data). MTT assays showed that whereas parental cells (451Lu
and Mel1617) were highly sensitive to BRAF inhibition by 885
(IC50 0.01–0.1 mM), melanoma cells that had been chronically
treated with 885 (451Lu-R and Mel1617-R) required higher
doses of the drug for partial growth inhibition (IC50 5–10 mM)
(Figures 1 B and 1C). Chronic treatment of additional BRAFV600E
melanoma cell lines with 885 led to the emergence of drug resis-
tance (Figures S1A–S1C and Table S1). Cell cycle analysis
showed that although treatment with 1 mM of 885 led to a
G0/G1 cell cycle arrest after 24 hr (p < 0.05) and an increase in
the percentage of cells in the SubG1 fraction after 72 hr (p <
0.05) in 451Lu and Mel1617 parental cells, it had no significant684 Cancer Cell 18, 683–695, December 14, 2010 ª2010 Elsevier Inceffect on 451Lu-R and Mel1617-R cells (p > 0.05) (Figure 1D;
Figures S1D and S1E).
Cells chronically treated with the BRAF inhibitor 885 exhibited
cross-resistance to other specific BRAF inhibitors, including
PLX4720 (PLX) (Tsai et al., 2008) as well as two other BRAF inhib-
itors currently in clinical trials (not shown). Treatment of parental
cells with PLX notably reduced viability (IC50 100–500 nM) of
BRAFV600E mutant melanomas. However, PLX had no major
effect on 885-resistant cells (IC50 > 5 mM) (Figures 1E and 1F).
These data demonstrate that chronic treatment with a specific
BRAF inhibitor can lead to development of drug resistance to
multiple selective BRAF inhibitors in melanomas harboring
BRAFV600E mutations that were initially highly sensitive to these
compounds.
SB-590885-Resistant Cells Proliferate, Form Colonies
in Soft Agar, and Grow in 3D Collagen-Based Matrices
Despite BRAF Inhibition
To further characterize the growth properties of melanoma cells
with acquired resistance to BRAF inhibitors, we investigated the
effects of BRAF inhibition on proliferation, anchorage indepen-
dent growth, and growth in a 3D-tumor-like microenvironment
of the parental metastatic melanoma and 885-resistant cell lines
(Figure 2). Whereas treatment of 451Lu parental cells with 885
led to inhibition of proliferation (Figure 2A; p < 0.05), it did not
affect the growth of 451Lu-R cells (p > 0.05). 451Lu-R cells
exhibited similar growth rates as untreated 451Lu cells, even
when grown in the presence of 885 (p > 0.05). Anchorage-
independent growth assays demonstrated that although BRAF
inhibition precluded the ability of parental cells to form colonies
in soft agar (Figure 2B; p < 0.05), it did not affect the colony-form-
ing ability of cells resistant to BRAF inhibitors (p > 0.05). Previous
studies have shown that growth of melanoma cells as 3D
collagen-implanted spheroids more closely mimics the in vivo
behavior of melanoma tumors and considerably increases their
drug resistance (Horning et al., 2008; Smalley et al., 2006). We
examined the effect of BRAF inhibition by 885 in parental and
resistant cells grown as multicellular spheroids in 3D collagen-
basedmatrices (Figure 2C). Consistent with our previous studies
(King et al., 2006), treatment of the BRAFV600E mutant cells with
885 for 72 hr led to a dose-dependent loss of cell viability. In
contrast, BRAF-inhibitor resistant spheroids remained viable.
The growth properties of these cells both in 2D and 3D, and their
ability to form colonies in soft agar, demonstrate that treatment
with BRAF inhibitors leads to acquired drug resistance and the
emergence of cells able to grow and proliferate even under
anchorage-independent conditions.
BRAF-Inhibitor-Resistant Melanomas Switch Among
RAF Isoforms to Activate the MAPK Pathway
and Induce Proliferation
To investigate the molecular basis underlying acquired resis-
tance to BRAF inhibitors, we analyzed the effect of 885 on
downstream ERK activation in both parental and resistant cells.
Treatment of 451Lu cells with 885 caused a dose-dependent
inhibition of ERK activation (Figure 3A). In contrast, ERK re-
mained phosphorylated in the resistant cells despite treatment
with high doses of the BRAF inhibitor up to 10 mM, raising the
possibility that ERK activation could be mediated by a kinase.
Figure 1. BRAFV600E Mutant Melanomas Chronically Treated with BRAF Inhibitors Develop Drug Resistance
(A) Schematic representation of generation of SB-590885 (885) resistant cells.
(B andC) Sensitivity to BRAF inhibition of parental (blue) and 885 chronically treatedmelanoma cells (red) was assessed byMTT assays. Relative growth (RG) was
calculated as the ratio of treated to untreated cells at each dose for each replicate. Data are represented as mean ± standard error of mean (SEM) (n = 7). (B) At all
doses <10 mM, RG was significantly lower for 451Lu cells (p < 0.05). (C) At all doses RG was significantly lower for Mel1617 cells (p < 0.05). The resistant cells are
indicated by the name of the parental cell line followed by ‘‘R’’.
(D) Cells were treated with dimethyl sulfoxide (DMSO) or 1 mM 885 for 24 hr, stained with propidium iodide and analyzed for cell cycle progression by flow
cytometry. Response to treatment between the two cell lines was not significantly different (p > 0.05). The percentage of cells in G0/G1 and SubG1 are shown.
Representative cell cycle plots from one experiment are shown.
(E and F) Sensitivity of 451Lu (E) andMel1617 (F) parental and the corresponding 885-resistant cells to PLX4720was assessed byMTT assays as in (B). Cells were
treated with the indicated concentrations of PLX4720 (nM). Data represent mean of three independent experiments ± SEM. Parental and resistant cells were
significantly different (p < 0.05) at doses > 1 mM. See also Figure S1.
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Figure 2. Growth Properties of SB-590885-Resis-
tant Melanoma Cells
(A) Cells were treated with 1 mM 885 for 6 days, fixed at
the indicated days, stained with crystal violet, and photo-
graphed. Cell number was determined relative to day 0.
Data represents mean ± SEM (n = 3). p < 0.05 when
comparing 451Lu + 885 with 451Lu + DMSO or
451Lu-R +/ 885 at day 6; p > 0.05 when comparing
451Lu-R +/ 885 with 451Lu. Scale bar represents
800 mm.
(B) 451Lu parental and resistant cells were grown in soft
agar for 12 days +/ 1 mM 885. Anchorage-independent
growth was assessed by counting individual colonies
using ImagePro-Plus software in triplicate and normalizing
to vehicle controls for each condition. Data represent
mean ± SEM (n = 3), p < 0.05 for DMSO-treated versus
885-treated parental cells, and p > 0.05 for parental
DMSO-treated versus resistant cells. Scale bar represents
10 mm.
(C) 451Lu (left) and 451Lu-R (right) collagen-embedded
spheroids were treated with the indicated concentrations
of 885. Spheroids were stained with calcein-AM and
imaged with a confocal microscope. Relative viability
was assessed based on the % of cells remaining after
treatment and morphological appearance. Scale bar
represents 150 mm.
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obtained with 885, as well as to determine if ERK activation
was dependent on BRAF, we knocked-downBRAF using shRNA
(Figure 3B). Short hairpin RNA-mediated BRAF knockdown led
to inhibition of ERK phosphorylation in 451Lu parental cells,
but had no effect on 451Lu-R cells, suggesting that ERK activa-
tion is BRAF-independent in these cells.
We also examined if secondary mutations in Braf could be
associated with development of resistance to BRAF inhibitors.
Mutational analysis of exons 6 and 11–17 in the BRAF gene was
performed in all parental and resistant cell lines. These exons
represent those in which mutations in melanoma and genetic
syndromes have been described. We did not identify any muta-
tions beyond V600E (Table S1). Moreover, we sequenced other
genes commonly mutated in melanoma, including, Nras (exons
2 and 3), c-kit (exons 9, 11, 13, 14, 17, and 18), and Pten (exons
5–9) and did not find de novo mutations in these genes. We also
found that resistance to BRAF inhibitors was not associated with
changes in copy number of Braf, Nras, c-kit, or Pten (not shown).
We noted that short-term treatment with 885 at 1–5 mM led to
a decrease in CRAF protein levels in 451Lu cells, whereas CRAF686 Cancer Cell 18, 683–695, December 14, 2010 ª2010 Elsevier Inc.levels remained steady or in some instances
even increased in the resistant cells (Figure 3A).
Similarly, knockdown of BRAF using shRNA,
led to an increase in CRAF protein levels in
both the parental and resistant cells (Figure 3B;
sh-3). We next examined the possibility that
CRAF could be mediating ERK activation in
response to BRAF inhibition (Montagut et al.,
2008). Lentiviral-mediated infection of 451Lu-R
cells with CRAF shRNA inhibited CRAF expres-
sion, but had no effect on ERK activation
(Figure 3C). Treatment of CRAF shRNA-infected cells with 885 had no effect on phospho-ERK levels,
indicating that 885-resistant cells can activate the MAPK
pathway independently of BRAF and CRAF. Similarly, infection
of 451Lu-R cells with three different ARAF shRNAs led to knock-
down of this RAF isoform, but had no effect on phospho-ERK
(Figure 3D). Inhibition of BRAF activity by 885 in conjunction
with ARAF-knockdown did not preclude phosphorylation of
ERK in 451Lu-R cells (Figure 3D, lanes 6–8). Given that 885-
resistant cells are able to activate ERK despite inhibition of
either one or two RAF isoforms, we hypothesized that these
cells only require one active RAF isoform to activate the
MAPK pathway. To test this hypothesis, we sequentially in-
fected 451Lu-R cells with lentivirus carrying shRNAs against
CRAF followed by infection with shRNAs against ARAF (Fig-
ure 3E). Simultaneous shRNA-mediated inhibition of CRAF
and ARAF did not have a significant effect on phospho-ERK
levels; however, treatment of these cells with 1 mM 885 resulted
in downregulation of ERK phosphorylation (Figure 3E). We
conclude that inhibition of ERK activity in BRAF-inhibitor-
resistant cells requires concomitant abrogation of all three RAF
isoforms. Together these data argue that cells with acquired
Figure 3. Abrogation of ERK Activity in SB-590885-
Resistant Melanomas Requires Inhibition of all
Three RAF Isoforms and Leads to Cell Cycle Arrest
(A) 451Lu and 451Lu-R cells were treated with increasing
concentrations of 885. Cells lysates were analyzed by
immunoblotting.
(B) 451Lu and 451Lu-R cells were infected with either a
control [C] lentiviral shRNA or 3 different clones targeting
BRAF (1, 3, or 4). Cell lysates were analyzed by immuno-
blotting.
(C) 451Lu-R cells were infected with lentiviral shRNA
directed against CRAF or GFP. Infected cells were treated
with 1 mM885 (+) or left untreated () for 24 hr. Cell lysates
were analyzed by immunoblotting with antibodies against
CRAF, pERK, and total ERK (loading control).
(D) 451Lu-R cells were infected with lentiviral shRNA
against ARAF (clones 1, 4, and 5) or GFP. Infected cells
were treated with 1 mM 885 or DMSO for 24 hr. Cells
were harvested, lysed, and analyzed by immunoblotting
with antibodies against ARAF, BRAF, CRAF, pERK, and
total ERK (loading control).
(E) 451Lu-R cells were sequentially infected with lentiviral
shRNA directed against CRAF followed by ARAF. Infected
and control cells were then treated with 1 mM 885 for 24 hr
(+) or left untreated (). Cell lysates were analyzed by
immunoblotting.
(F) After lentiviral infection, cells were treated with DMSO
or 1 mM 885 for 72 hr. Cells were harvested, fixed, stained
with propidium iodide, and analyzed by flow cytometry.
The percentage of cells in G0/G1 is indicated for each
condition. See also Figure S2.
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ties and indistinctly use any of the three active RAF isoforms
to trigger ERK activation. Although inhibition of one or two
RAF isoforms did not considerably affect cell cycle progression
in 451Lu-R cells, simultaneous inhibition of all three RAF iso-
forms led to G0/G1 cell cycle arrest; no major increase in the
number of cells accumulating in the SubG1 fraction of the cell
cycle was observed (Figure 3F). We conclude that any RAF
isoform can activate ERK and regulate proliferation of mela-
noma cells resistant to BRAF inhibitors.
To confirm that 885 resistant cells remain dependent on
MAPK activation for proliferation, we examined the effect of
MEK inhibition in parental and resistant cells using the MEK
inhibitors GSK1120212 (212), AZD6244 (AZD), and U0126 (UO)
(Figure 4; Figure S3). 212 is a potent and selective allosteric
MEK1/2 inhibitor currently in phase I/II clinical trials for solid
tumors and lymphoma (Clinicaltrials.gov; Figure 4A). In bio-
chemical assays, 212 inhibits MEK1 activation by RAF (IC50 =Cancer Cell 18, 683–0.7 ± 0.1 nM) and phospho-MEK1 kinase
activity (IC50 = 10 ± 2 nM) (not shown). 212
blocks full activation of MEK1/2 by inhibiting
phosphorylation of S217 and shows no signifi-
cant activity against 200 unique kinases
when tested at 10 mM. Treatment with 212 in-
hibited ERK phosphorylation and decreased
viability in both parental and resistant cell lines
(Figures 4B-4D; Figure S3A).
Consistent with these data, MEK inhibition by
212 resulted in G0/G1 cell cycle arrest inparental and resistant melanomas (Figure 4E; p < 0.05).
However, a 10-fold higher dose of 212 was required to inhibit
ERK phosphorylation, cell viability, and G0/G1 cell cycle arrest
in Mel1617-R cells. Interestingly, although treatment with 212
significantly increased the number of cells in SubG1 in the
parental cells (p < 0.05), it did not have a considerable effect
on the resistant cells (p > 0.05). To confirm our findings with
212, we used two additional MEK inhibitors (AZD6244 and
UO126) displaying different mechanisms of action. Treatment
of parental and resistant cells with AZD6244 or UO126 led to
inhibition of ERK phosphorylation (Figure 4B and Figures S3A–
S3C), G0/G1 cell cycle arrest (Table S2) and decreased cell
viability (Figure S3D). Similar to the results with 212, a 10-fold
higher dose of AZD6244 was required to inhibit phosphorylation
of ERK and viability of Mel1617R cells compared to their parental
counterparts. Treatment of 885-sensitive and -resistant mela-
nomas in a 3D context with 212, AZD6244, or U0126 over
72 hr showed that both parental and 885-resistant cells were695, December 14, 2010 ª2010 Elsevier Inc. 687
Figure 4. The MEK Inhibitor GSK1120212 Pre-
vents ERK Activation and Proliferation in Both
SB-590885 Sensitive and Resistant Cell Lines
(A) Chemical structure of GSK1120212 (212).
(B) 451Lu and 451Lu-R cells were treated with 1 mM 885,
10 mM UO126 (UO), or increasing concentrations of
212 (nM) for 24 hr. Cell lysates were analyzed by immuno-
blotting.
(C and D) Sensitivity to the MEK inhibitor 212 was as-
sessed by MTT assays as in Figure 1. Data represent
means ± SEM (n = 7).
(E) Parental and 885-resistant cells were treated with
212 for 72 hr, stained with propidium iodide, and analyzed
by flow cytometry. Data represent mean ± SEM (n = 3);
*p < 0.05 when compared to DMSO-treated cells.
(F) 451Lu and 451Lu-R collagen-embedded spheroids
were treated with the indicated concentrations of 212 for
72 hr. Cells were imaged with a confocal microscope.
See also Figure S3 and Table S2.
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tumor-like microenvironment (Figure 4F and Figure S3E and
S3F). These results suggest that although ERK activity remains
sensitive to MEK inhibition in BRAF-inhibitor resistant cells,
abrogating MAPK signaling has primarily cytostatic effects and
raises the possibility that additional pathways may promote
survival of these cells.688 Cancer Cell 18, 683–695, December 14, 2010 ª2010 Elsevier Inc.IGF-1R Leads to Induction of Prosurvival
Signals in BRAF Inhibitor Resistant Cells
To investigate if additional pathways were stim-
ulated in response to chronic BRAF inhibition,
we examined the activation of several tyrosine
kinase receptors (RTKs). Analysis of RTK phos-
phorylation using an antibody array suggested
that some RTKs were differentially phosphory-
lated in the resistant cells compared to their
parental counterparts (Figure 5A). Using phar-
macological inhibitors of these receptors, we
found that only treatment with the IGF-1R inhib-
itors cyclolignan picropodophyllin (PPP; Girnita
et al., 2004) or tyrphostin AG1024 (Parrizas
et al., 1997) (Figure 5B; Figures S4A and S4B;
data not shown) led to decreased viability of
melanomas resistant to BRAF inhibitors.
Consistent with an established role of IGF-1
mediating proliferation and survival in mela-
noma (Hilmi et al., 2008; Satyamoorthy et al.,
2001), PPP had a partial effect decreasing
viability in both parental and resistant mela-
noma spheroids (Figures S4D and S4E). We
next evaluated both the surface expression of
IGF-1R and phosphorylation of IGF-1R at
Tyr1131, which is indicative of kinase activation.
Analysis of IGF-1R surface expression by flow
cytometry revealed that BRAF-inhibitor resis-
tant cells upregulate IGF-1R (Figure 5C).
Moreover, IGF-1R remained phosphorylated in
the resistant cells after treatment with 885compared with parental cells (Figure 5D; Figure S4C). We did
not find mutations in Igf-1r, nor did we observe changes in
copy number, suggesting that the regulation of IGF-1R is medi-
ated at least in part by increased surface expression of the
receptor in the BRAF-inhibitor resistant cells. Analysis of IGF-1
and IGF-1R mRNA by qRT-PCR indicated that even short-term
treatment of parental cells with 885 led to an increase in both
Figure 5. Enhanced IGF-1R in Cells Chronically
Treated with BRAF Inhibitors
(A) 451Lu and 451Lu-R cells were treated with 1 mM885 or
DMSO (D) for 24 hr. Whole-cell lysates were incubated on
RTK antibody arrays. Each RTK antibody is spotted in
duplicate. Positive RTK dots are circled in red and indi-
cated by a number; the corresponding RTKs are listed
next to the arrays.
(B) Sensitivity to the IGF-1R inhibitor PPP (mM) or the
c-Met inhibitor PHA (mM) was evaluated in 451Lu-R and
Mel1617-R by MTT assays as in Figure 1. Data represent
means ± SEM (n = 7).
(C) IGF-1R surface expression was assed by indirect
immunofluorescence in parental (black) and resistant
(red) melanomas treated with 885 (1 mM) for 20 hr. Dotted
lines denote control rabbit antibody for the corresponding
parental or resistant cells. Numbers on the top right
indicate percent positive surface expression of IGF-1R in
parental (black) and resistant (red) cells.
(D) Expression and phosphorylation of IGF-1R was as-
sessed in parental (P) and resistant (R) melanomas treated
with 885 (1 mM) for 20 hr. Cell lysates were analyzed by
immunoblotting with the indicated antibodies. See also
Figure S4.
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increase does not seem to be sufficient to persistently activate
the IGF-1 system, as it does not correlate with increased
IGF-1R protein expression or activation in parental cells treated
with 885. Similarly, analysis of IGF-1 and IGF-1R mRNA by
qRT-PCR in resistant cells showed a modest increase in
mRNA levels for both growth factor and receptor that did not
correlate with protein expression. These results suggest that
the persistent IGF-1R activity in cells resistant to BRAF inhibitorsCancer Cell 18, 683–is most likely regulated at the posttranscrip-
tional level and that additional factors, such as
IGFBP expression, may be required to fully
engage the system. Indeed, qRT-PCR analysis
showed that IGFBP-3 mRNA was increased
after acute treatment of parental cells with
885, whereas it was downmodulated in the
resistant cells (Figure S4F). IGFBP3 negatively
regulates the activation of IGF-1R by seques-
tering IGF-1 and preventing ligand binding to
the receptor (Karas et al., 1997); thus, the regu-
lation of IGFBP3 may be one of several factors
modulating IGF-1-mediated signaling in
response to BRAF inhibition.
IGF-1R plays an important role in tumorigen-
esis, resistance to apoptosis and resistance to
anti-cancer agents (Casa et al., 2008; Pollak,
2008; Tao et al., 2007). IGF-1R has gained
increasing attention as a promising target in
cancer therapy, but its role as a therapeutic
target in melanoma has not been systematically
explored. IGF-1R can activate both the MAPK
and PI3K pathways, both of which play critical
roles in melanomagenesis. We examined the
effect of IGF-1R inhibition on MAPK- and
PI3K-mediated signaling. Treatment with PPPor AG1024 had no effect on ERK activation in 885-resistant cells
(Figure 6A; Figures S4C, S5A, and S5B). However, phosphoryla-
tion of AKT was inhibited by treatment with PPP (Figure 6A).
Consistent with our results using IGF-1R small molecule
inhibitors, expression of dominant negative (dn) IGF-1R (Min
et al., 2003) in 885-resistant cells did not inhibit MEK and ERK
phosphorylation (Figure 6B), but had an inhibitory effect on
AKT phosphorylation (Figure S5C). Overexpression of the
IGF-1R ligand, IGF-1, in Mel1617 parental cells led to increased695, December 14, 2010 ª2010 Elsevier Inc. 689
Figure 6. IGF-R Mediates PI3K Signaling in BRAF-Inhibitor Resistant Cells
(A) Mel1617-R cells were treated with increasing concentrations of PPP (mM) as single agent or in combination with 0.1 mM212. The effect of IGF-1R inhibition on
MAPK, AKT, and Bcl-2 family proteins was assessed by immunoblotting.
(B) Mel1617-R cells were infected with adenoviruses encoding dominant negative (dn) IGF-1R at 10 or 100 multiplicity of infection (moi), or LacZ as a negative
control. Infected cells were treated 48 hr postinfection with 0.1 mM212 or left untreated. Cells lysates were analyzed by immunoblotting; cl-PARP, cleaved PARP.
(C) Parental Mel1617 cells were infected in serum-free medium with adenoviruses encoding IGF-1 at 10, 100, or 500 moi. Infected cells were serum starved for
48 hr and then treatedwith 1 mM885 or left untreated. Cells lysates were analyzed by immunoblotting. Doted lines indicate where blot was cut to remove an empty
lane. See also Figure S5.
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phosphorylation (Figure 6C; Figures S5C and S5D). Together
these data suggest that persistent IGF-1R signaling induces
PI3K/AKT activation in V600E mutant melanomas-resistant to
BRAF inhibitors. However, our data do not preclude the possi-
bility that additional factors could also affect interregulation of
IGF-1R and PI3K in BRAF inhibitor resistant cells.
Considering that IGF-1R and PI3K/AKT play important roles
mediating cell survival, we examined the effect of MEK and
IGF-1R inhibition on the expression of some Bcl2-family
members known to be important for melanoma survival,
including Mcl-1, BAD, and BIM (Boisvert-Adamo et al., 2009).
Mel1617-R cells expressed high levels of phospho-BAD and
Mcl-1, neither of which were completely inhibited by treatment
with 885 (Figure 6A; Figures S5A and S5B). Unphosphorylated
BAD binds and inactivates the prosurvival factors Bcl-2 and
Bcl-xl promoting apoptosis; phosphorylated BAD associates
with 14-3-3 allowing unbound Bcl-2/Bcl-xl to promote survival.
Although inactivation of MEK/ERK by 212 or AZD6244 was
sufficient to inhibit BAD phosphorylation and to induce BIM, inhi-
bition of IGF-1R signaling did not have any considerable effect
on these pro-apoptotic factors (Figures 6A and 6B; Figures
S5A S5B). Inhibition of either MEK or IGF-1R led to a partial
downregulation of the pro-survival factor Mcl-1 (Figures 6A
and 6B; Figures S5A and S5B). Moreover, concomitant inhibition
of MEK and IGF-1R/AKT-mediated signaling had an additive
effect downregulating Mcl-1 in Mel1617-R cells (Figures 6A
and 6B; Figures S5A and S5B). MEK and IGF-1R appear to
cooperate and promote survival of melanomas resistant to690 Cancer Cell 18, 683–695, December 14, 2010 ª2010 Elsevier IncBRAF inhibitors; whereas MEK alone regulates BIM and BAD,
both pathways jointly regulate Mcl-1 expression. Overexpres-
sion of IGF-1 decreased BIM expression, but it did not preclude
the ability of 885 to induce BIM (Figure 6C). Although treatment
of Mel1617 cells with 885 resulted in partial downregulation of
Mcl-1, overexpression of IGF-1 led to increased Mcl-1 levels,
which could not be downregulated by 885 alone. These results
suggest that MEK and IGF-1R cooperate to promote cell survival
in part through the coordinated regulation of Mcl-1. Our data
suggest that coinhibition of MEK and IGF-1R shifts the balance
of apoptotic BH3-family member activity toward cell death,
although other survival factors in addition to BAD, BIM, and
Mcl-1 could also be regulating survival of BRAF-inhibitor resis-
tant melanomas.
Simultaneous MEK and IGF-1R/PI3K Inhibition Leads to
Cytotoxicity in Melanomas Resistant to BRAF Inhibitors
To investigate if combined MEK and IGF-1R inhibition could
induce cytotoxic effects on 885-resistant cells, 451Lu-R and
Mel1617-R cells were treated with MEK inhibitors (212 or
AZD6244), an IGF-1R inhibitor (PPP), or the potent pan-PI3K
inhibitor GSK2126458 (458) (Knight et al., 2010), as single agents
or in combination. Treated cells were analyzed for cell cycle
progression (Figure 7A;Tables S3 andS4) and Annexin-V expres-
sion (Figure 7B; Figure S6A). Cell-cycle analyses established that
although BRAF inhibition did not have a significant effect on
proliferation or induction of apoptosis in 885-resistant cells (p >
0.05; Figure 1D; Figures S1D and S1E), MEK inhibition in BRAF
inhibitor-resistant cells was sufficient to induce cell-cycle arrest.
Figure 7. Coinhibition of IGF-1R/PI3K and MEK Induces Cytotoxicity in BRAF-Inhibitor Resistant Cells
(A) Cell cycle profiles of 451Lu-R cells treated with DMSO, 1 mM 212, 1 mM PPP, or a combination of both inhibitors for 72 hr. Percentage of cells in G0/G1 and
SubG1 are shown.
(B) 451Lu-R cells were treated with DMSO, 212 (1 mM), PPP (1 mM), or both inhibitors at the same concentrations for 72 hr. Cells were collected and apoptosis was
assessed by Annexin-V staining. Numbers in each quadrant indicate percentage of cells. Representative results of two independent experiments are shown.
(C) Collagen-embeddedMel1617-R spheroids were treatedwith DMSO, 10 mM885, 1 mM212, 1 mM458, or 1 mM212 + 1 mM458 for 72 hr. Cells were imagedwith
a confocal microscope. Scale bar represents 150 mm. See also Figure S6, and Tables S3 and S4.
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exposure to 212 (72 hr) led to minor increases in cell death as
determined by the number of cells accumulating in the SubG1
fraction of the cell cycle as well as an increase in Annexin
V-positive cells (Figures 7A and 7B) in resistant cells. Treatment
of BRAF inhibitor-resistant melanomas with PPP increased the
number of cells in the G2/M phase of the cell cycle, the number
of cells in the SubG1 phase (Figure 7A;Table S3 and S4), and
Annexin V-positive cells (Figure 7B; Figure S6A). Concomitant
MEK and IGF-1R inhibition by 212 and PPP led to an increase
in the fraction of cells in the SubG1 phase of the cell cycle, as
well as an increase in the number of Annexin V-positive cells, indi-
cating that coinhibition of MEK and IGF1-R leads to increased
melanoma cell death. Similar results were observed when inhib-
iting MEK with AZD6244 in combination with PPP (Figure S6A)Canor by combined treatment with 212 and 458 (Table S4).
We confirmed the results from our 2D-platforms by using
3D-spheroid assays to determine if combined MEK and IGF-1R
or MEK and PI3K inhibition could induce cytotoxicity in mela-
noma cells resistant to BRAF inhibitors in the context of a
3D-collagen matrix. Simultaneous treatment with 212 and 458
confirmed that BRAFV600E cells resistant to BRAF inhibitors
undergo apoptosis (assessed by the percentage of viable cells
remaining after treatment and morphological appearance) in
response to combination treatment to a much greater extent
than when treated with each individual compound (Figure 7C;
Figure S6B). Treatment with PPP in combination with 212 or
AZD6244 resulted in decreased cell viability in 885-resistant
melanoma spheroids (Figures S6C and S6D). The collective
data suggest that cotargeting MEK and IGF-1R/PI3K can resultcer Cell 18, 683–695, December 14, 2010 ª2010 Elsevier Inc. 691
Figure 8. Increased IGF-1R Expression and Phos-
phorylation of AKT in Relapsed Patient Samples
Paired tumor samples (patient 1, Table S5) taken before
treatment (pretreatment, subcutaneous back lesion) and
drug resistant (post-relapse, small bowel) were analyzed
for IGF-1R expression or phospho-AKT by immunohisto-
chemistry. Low magnification representative images are
shown on the left (scale bar represents 500 mm) and higher
magnification images are on shown on the right (scale bar
represents 50 mm). See also Figure S7 and Table S5.
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Acquired Resistance to BRAF Inhibitorsin striking antimelanoma activity in melanomas resistant to BRAF
inhibitors.
Increased IGF-1R Expression and Phosphorylation of
AKTCorrelatewith Resistance to BRAF Inhibitors in One
of Five Paired Tissue Samples from Relapsed Patients
To evaluate the potential clinical implications of our in vitro
findings, we examined by immunohistochemistry (IHC) tumor
biopsies from five patients with metastatic melanoma treated
with the BRAF inhibitor PLX4032. The tumors of all five patients
were BRAFV600E+ and initially responded to treatment with
PLX4032 (Table S5) but relapsed after 4–15 months, suggesting
that they developed resistance to the BRAF inhibitor. Five sets of
paired tumor samples (pretreatment and post-relapse) were
stained and analyzed for IGF-1R and pAKT blindly by a patholo-
gist. We found increased levels of IGF-1R and pAKT in post-692 Cancer Cell 18, 683–695, December 14, 2010 ª2010 Elsevier IncT
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patient 1 in Table S5). This patient did not have
secondary Braf mutations, Nras mutations, or
changes in Pten status. Patient 1 had brain
and subcutaneous metastases but no other
organ involvement before enrolling in the study.
The patient was dose-escalated from 160 mg of
PLX4032 twice a day to 720mg twice a day, had
a good response to the BRAF inhibitor as
judged by CT scans (Figures S7A and S7B),
and had a progression-free survival (PFS) of
466 days, but relapsed on PLX4032. A pro-
gressing intra-abdominal lesion was not seen
at presentation (Figure S7C), but was then
observed at progression using PET/CT scan
fusion (Figure S7D). These findings are consis-
tent with our in vitro data, where increased
IGF-1R expression and phosphorylation of
AKT, in the absence of changes in Braf, Nras,
or Pten mutation status, is associated with
resistance to BRAF inhibitors. Additionally, we
also found increased IGF-1R levels in post-
relapse samples of patient 5 (Figures S7E and
S7F); however, pAKT levels were not increased.
The absence of pAKT in the post-relapse biopsy
of patient 5 could be due to the rapid loss of
phospho-proteins in FFPE human tissue
samples that often occurs during the process-
ing of the sample (Jones et al., 2008).
Partial information on Pten status was
available for patients 2, 4, and 5 (Table S5).he post-relapse sample of patient 2, which did not have
econdary mutations inBraf ormutations inNras, had a homozy-
ous loss of Pten that was not present in the pretreatment
ample. Interestingly, there was an increase in pAKT in the
ost-relapse sample of this patient without a concomitant
F-1R increase (not shown). Although the number of specimens
xamined was small, due to limited access to human samples,
ur findings suggest that increased expression of IGF-1R and
ctivation of the IGF-1R/PI3K/AKT pathway could occur in
ssociation with development of resistance to BRAF inhibitors
the clinical setting.
ISCUSSION
e report that BRAFV600E melanomas chronically treated with
specific BRAF inhibitor acquire cross-resistance to several
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BRAF inhibition is associated with enhanced IGF-1R and PI3K/
AKT activity in melanoma cells resistant to BRAF inhibitors. We
propose that drug combinations cotargeting MEK and IGF-1R/
PI3K may offer valid therapeutic approaches to overcome resis-
tance to BRAF inhibitors.
Acquired resistance to anticancer agents is frequently encoun-
tered in clinical practice. Resistance to kinase inhibitors is often
associated with secondary mutations in the target gene, which
render the kinase insensitive to the inhibitor (EngelmanandSettle-
man, 2008). However, in our in vitro system, we did not find
secondary mutations in Braf that could explain resistance to
BRAF inhibitors. We also did not identify de novo mutations or
changes in copy number in Nras, kit, or Pten, three oncogenes
commonly associated with melanoma. BRAFV600E promotes
persistent MAPK activity, leading to increased proliferation and
survival. AcuteBRAFV600E inhibitionbygenetic depletionor kinase
inhibitors can lead to cell cycle arrest and, in some instances,
apoptosis in melanomas addicted to this oncogene (Bollag
et al., 2010; Hingorani et al., 2003; King et al., 2006; Lee et al.,
2010; Sumimoto et al., 2004; Tsai et al., 2008; Yeh et al., 2006).
Our studiesdemonstrate that uponchronicBRAF inhibition,mela-
nomas rewire their signaling circuitry to utilize one of the other two
RAF isoforms, ARAF or CRAF, to overcome the effect of BRAF
inhibition.
Our data are consistent with a model whereby melanomas are
initially addicted to the BRAF/MAPK pathway. If BRAF is
repressed, melanomas trigger an alternative signaling program,
involving a kinase switch, which allows the addicted tumor to
continue to rely on MAPK for maintenance of the malignant
phenotype. Our findings have important therapeutic implications
as they highlight the relevance of MAPK signaling in melanoma
and argue that targeting the MAPK pathway constitutes a valid
therapeutic strategy.
Recent studies demonstrated that in the context of mutant
RAS, acute inhibition of BRAF kinase activity promotes altered
scaffolding and activation of CRAF, phosphorylation of ERK,
and oncogenesis (Hatzivassiliou et al., 2010; Heidorn et al.,
2010). Although Hatzivassiliou et al. (2010) and Heidorn et al.
(2010) suggested that BRAF inhibition does not activate CRAF
in V600E mutant cells, our studies indicate that BRAFV600E
melanomas can flexibly switch among the three different RAF
isoforms by a yet unidentifiedmechanism to overcome the effect
of chronic BRAF inhibition and activate the MAPK pathway.
Montagut et al. (2008) described a model of resistance to the
RAF inhibitor AZ628 through increased levels of CRAF protein.
We also observed increased CRAF levels in cells chronically
treated with the BRAF inhibitor 885. However, in our system,
shRNA-mediated inhibition of CRAF did not affect ERK activa-
tion or proliferation, as resistant cells can also switch to ARAF.
The differences between the two studies may be due to the
distinct molecular and genetic profiles of the cell lines used,
the mechanism of action of the drug used to target the tumor
cells, and/or the duration of treatment among other factors.
Our data demonstrate that under conditions of chronic BRAF
inhibition, melanomas rely on IR/IGF-1R-mediated survival
pathways to circumvent adverse conditions favoring cell death.
IGF-1R, which is expressed in all cells of melanocytic origin,
has been implicated in resistance to therapy in other neoplasia,Canincluding lung and breast cancer (Casa et al., 2008). Recently,
Sharma et al. (2010) have reported the existence of a subpopula-
tion of drug-tolerant cells that survive acute drug treatment via
engagement of IGF-1R signaling. The enhanced activity of
PI3K/AKT associated with chronic BRAF inhibition suggests
the possible existence of a negative crosstalk between the two
pathways. Crosstalk between MAPK and PI3K has been re-
ported in several cancer systems (Carracedo et al., 2008;
Cheung et al., 2008; Mirzoeva et al., 2009), but not much is
known in melanoma; this issue deserves further exploration.
BRAFV600E/PTEN+ melanomas, which are sensitive to BRAF
inhibitors, have low levels of pAKT (our unpublished data). In
contrast, melanoma cells that acquire resistance to BRAF inhib-
itors have enhanced levels of pAKT associated with increased
IGF-1R signaling. These observations raise the possibility that
IGF-1R/PI3K-mediated signaling in the context of chronic
BRAF inhibition promotes survival of BRAF inhibitor-resistant
melanomas, and cooperates with the MAPK pathway to support
drug resistance. Consistent with this notion, inhibitors of MEK
and IGF-1R or PI3K in combination were more effective inducing
cell death of BRAF-inhibitor resistant cells than when used as
single agents.
Although results from recent clinical trials with PLX4032 are
encouraging, responding tumors eventually develop resistance.
Increased expression of IGF-1R in post-relapse tumor biopsies
of two patients who developed resistance to PLX4032, one of
whom also had increased levels of phospho-AKT, constitute
proof-of-principle that IGF-1R/PI3K/AKT-mediated signaling
may be associated with resistance to BRAF inhibitors, and
provide insight into future therapies for the treatment of patients
who become refractory to these drugs. The absence of changes
in Braf, Nras, and Pten mutation status in patient 1 supports the
idea that a nongenetic mechanism can be underlying resistance
to BRAF inhibitors in some patients. Our findings suggest that
melanomas can respond to chronic BRAF inhibition through
dynamic changes by rewiring their signaling circuitry, allowing
the tumor cells to adapt to pharmacological challenges. Given
the high degree of heterogeneity and plasticity of melanoma, it
is likely that several mechanisms of resistance will arise in
response to chronic BRAF inhibition, raising challenges to our
quest in search of effective therapies for this malignancy. Of
note, homozygous loss of Pten and increased phospho-AKT
were identified inpost-relapsesamples inonepatient, suggesting
that alternative mechanisms leading to PI3K/AKT activation may
also be associated with acquired resistance to BRAF inhibitors.
Our studies and others’ demonstrate that targeting solely one
pathway is not sufficient to eradicate melanoma (Lasithiotakis
et al., 2008; Smalley et al., 2006). This study provides further
evidence that combination strategies targeting key oncogenic
pathways are required for successful therapy. Furthermore, our
findings provide a molecular rationale for combining MEK and
IGF-1R/PI3K inhibitors as we demonstrate that: (1) melanomas
areaddicted to theMAPKpathway—thus,shuttingoff thispathway
renders cells susceptible to apoptosis; (2) chronic BRAF inhibition
is associated with enhanced IGF-1R/PI3K-dependent survival
pathways as a protective cellular mechanism; and (3) concomitant
MEK and IGF-1R/PI3K inhibition shifts the balance toward
induction/activation of proapoptotic molecules and inhibition of
prosurvival factors in melanomas resistant to BRAF inhibitors.cer Cell 18, 683–695, December 14, 2010 ª2010 Elsevier Inc. 693
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promising approach, as these two signaling pathways cooperate
to drive tumor growth, survival, and resistance to therapy. Thus,
combination strategies targeting these two pathways merit
further evaluation as a potential approach to treat melanomas
refractory to BRAF inhibitors.
EXPERIMENTAL PROCEDURES
Reagents
SB-590885, GSK1120212, and GSK2126458 were provided by GlaxoSmithK-
line. PLX4720 was provided by Plexxikon. AZD6244 was synthesized by
Chemietek (Indianapolis, IN). U0126 was purchased from Promega (Madison,
WI); cyclolignan picropodophyllin (PPP), AG1024, and PHA-665752 were
purchased from Calbiochem (San Diego, CA).
Cell Culture
Human melanoma cell lines have previously been described (Iliopoulos et al.,
1989). Melanoma cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 5% fetal bovine serum. 451Lu and 451Lu-R clones were
isolated from single cells. Resistant cell lines were generated by treating
parental cells with increasing concentrations of 885. Cells with the ability to
grow in 1 mM of 885 were obtained 6 months after the initial drug exposure.
Resistant lines were maintained in the continuous presence of 1 mM 885, sup-
plemented every 72 hr. The consistency of cellular genotypes and identities
was confirmed by DNA fingerprinting using Coriell’s microsatellite kit.
Cell Growth/Viability, Colony Formation, and Apoptosis Assays
Cell viability was measured by MTT assays as previously described (Smalley
et al., 2009). For cell cycle and apoptosis analysis, melanoma cells were
treated with small molecule inhibitors for 24–72 hr as previously described
(Tsai et al., 2008). For Annexin V analysis, cells were stained with Annexin-
APC (Molecular Probes) and propidium iodide. Samples were subsequently
analyzed with an EPICS XL (Beckman-Coulter) apparatus.
Immunoblotting and Antibody Arrays
All antibodies used were from Cell Signaling Technology (Beverly, MA), except
b-Actin, which was purchased from Sigma (St. Louis, MO), and Mcl-1 from
Santa Cruz Biotechnology (Santa Cruz, CA). To identify the relative levels of
phosphorylation of RTKs, we used a human phospho-RTK array kit (ARRY-
001; R&D Systems Minneapolis, MN), according to manufacturer instructions.
3D Spheroid Growth/Survival Assays
Melanoma spheroids were prepared as previously described (Tsai, et al.,
2008). Collagen-embedded spheroids were treated with inhibitors for 72–
96 hr. Spheroids were imaged using a Leica TCS SP2 confocal microscope.
Lentivirus and Adenovirus Infection
Lentiviral shRNA constructs were obtained from Sigma. Recombinant adeno-
virus encoding Igf-1 has previously been described (Satyamoorthy et al.,
2001). Dominant-negative mutant Igf-1r adenoviral vector (DN-IGF-1R) was
a generous gift from Dr. Y. Adachi and described elsewhere (Lee et al., 2003).
Patients’ Samples
Tumor specimens collected to evaluate the pathology of melanoma and phar-
macodynamics of PLX4032, as well as clinical information from patients
treated with PLX4032 were obtained under institutional review board-
approved studies at Vanderbilt University Medical Center (Nashville, TN) and
Peter MacCallum Cancer Centre (Victoria, Australia). All patients provided
informed written consent. Mutational and immunohistochemical analysis are
described in the Supplemental Experimental Procedures.
Statistical Analysis
The analysis of variance (ANOVA) was used to identify significant experimental
factors including cell line, dose, day and/or experiment that influenced the
primary experimental outcomes. When the ANOVA model was significant,
pair-wise differences in experimental group means were evaluated using694 Cancer Cell 18, 683–695, December 14, 2010 ª2010 Elsevier IncTukey’s procedure controlling for multiple hypothesis tests. Statistical
analyses were done in SAS (version 9.2) using Proc ANOVA and Proc GLM.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental References, seven figures, and five tables and can be found
with this article online at doi:10.1016/j.ccr.2010.11.023.
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